RxDoctor Payments DataLook up a doctor →

Srinath Kadimi, MD

Neurology · Fairfield, CTNPI 1730144734

Payments from drug & device makers

$907,655in general payments, 2019–2025

Across 352 payments — averaging $2578.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roche TCRC, Inc.$558K
  • Genentech, Inc.$208K
  • Biogen$64K
  • AbbVie$41K
  • Novo Nordisk AS$20K
  • Eisai Inc.$10K
  • plus $6K from 33 others

What the payments were for

  • Speaking & faculty fees$23,59475%
  • Travel & lodging$3,42211%
  • Food & beverage$4,46714%
  • Education$300%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$907,655 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$142,503
Medicare patients
503
Services billed
8,320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant14$15,260
Rasagiline Mesylate47$12,610
Memantine Hcl289$10,909
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone22$8,228
Levetiracetam271$6,666
Carbidopa-LevodopaCarbidopa/Levodopa311$5,729
Mycophenolate Mofetil19$5,039
Donepezil Hcl406$4,018
Gabapentin131$3,431
Primidone68$3,240
Carbidopa-Levodopa ErCarbidopa/Levodopa44$2,726
Lacosamide18$2,572
Divalproex Sodium39$1,657
Carbamazepine35$1,459
AmantadineAmantadine Hcl18$1,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$41,270$15,26014 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$48$6,06031 claims
Upsher-smith Laboratories LLCTopiramate$13$1,13292 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 280 neurology providers in Connecticut.

Other neurology in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →